Nanexa AB (publ)

Yes, nothing makes the investment team happier than to see the duo Ando and Westberg on stage. I am of course talking about Nanexa's chairman Göran Ando and CEO David Westberg. Welcome gentlemen. Thank you. It was a nice introduction. We will present Q4 and the whole year for 2025. But you will also present preclinical semaglutide data. You will also talk about the deal with Moderna. We also take questions in English for those who are English speaking and the answers will therefore also be in English if the questions are. So just briefly, David, how would you describe 2025?

I think 2025 has been a fantastic year for us. We started this year with Liragluti data, GLP-1 data, clinical data. What we then assess is the first clinical data on a one-month formulation of GLP-1, which we also got attention from the American Diabetes Association in It was at the end of June, on a midsummer evening. We were in Chicago to present it. It was a poster presentation, but it was well visited. A lot of people took notice. It was a strong start to the year. You know that we have gone over from Liraglutide to Semaglutide. Very good decisions from the management and board. Semaglutide long-acting is even more commercially feasible, so very strong. And then we added the deal with Moderna, which I think is fantastic. It is a validation of the technology of us as a company and is also a very interesting area to work in with mRNA. And Moderna as a company is also fantastic.

Thank you. Please introduce yourself and see you at the Q&A afterwards.